Elinogrel: Pharmacological principles, preclinical and early phase clinical testing

Future Cardiology

Volumn 6, Issue 4, 2010, Pages 445-453

  Ueno, Masafumi ^a   Rao, Sunil V ^b   Angiolillo, Dominick J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

acute coronary syndrome; antiplatelet therapy; elinogrel; P2Y12 receptor antagonist; platelet

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CANGRELOR; CLOPIDOGREL; ELINOGREL; PRASUGREL; TICAGRELOR; TICLOPIDINE; UNCLASSIFIED DRUG; P2RY12 PROTEIN, HUMAN; PURINERGIC P2 RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR; QUINAZOLINONE DERIVATIVE; SULFONAMIDE;

ACUTE CORONARY SYNDROME; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG SCREENING; DRUG STRUCTURE; DRUG URINE LEVEL; HEART MUSCLE ISCHEMIA; HUMAN; LOADING DRUG DOSE; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; THROMBOSIS; UNSPECIFIED SIDE EFFECT; CARDIOVASCULAR DISEASES; CLINICAL TRIAL (TOPIC);

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; PLATELET AGGREGATION INHIBITORS; QUINAZOLINONES; RECEPTORS, PURINERGIC P2; SULFONAMIDES; PURINERGIC P2 RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12;

EID: 77954510334     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.10.67     Document Type: Review

References (44)

1. Angiolillo DJ, Ueno M, Goto S: Basic principles of platelet biology and clinical implications. Circ. J. 74(4), 597-607 (2010).
2. Born GV: Adenosine diphosphate as a mediator of platelet aggregation in vivo: an editorial view. Circulation 72(4), 741-746 (1985).
3. Hechler B, Cattaneo M, Gachet C: The P2 receptors in platelet function. Semin. Thromb. Haemost. 31(2), 150-161 (2005).
4. Gachet C: Regulation of platelet functions by P2 receptors. Annu. Rev. Pharmacol. Toxicol. 46, 277-300 (2006).
5. Conley PB, Delaney SM: Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis. Curr. Opin. Hematol. 10(5), 333-338 (2003).
6. Rolf MG, Mahaut-Smith MP: Effects of enhanced P2X1 receptor Ca2+ influx on functional responses in human platelets. Thromb. Haemost. 88(3), 495-502 (2002).
7. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH; CLASSICS Investigators: Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 102(6), 624-629 (2000).
8. Cadroy Y, Bossavy JP, Thalamas C, Sagnard L, Sakariassen K, Boneu B: Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation 101(24), 2823-2828 (2000).
9. Yusuf S, Zhao F, Mehta SR et al.: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345(7), 494-502 (2001).
10. Chen ZM, Jiang LX, Chen YP et al.: Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366(9497), 1607-1621 (2005).
11. Sabatine MS, Cannon CP, Gibson CM et al.: Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med. 352(12), 1179-1189 (2005).
12. Mehta SR, Yusuf S, Peters RJ et al.: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358(9281), 527-533 (2001).
13. Steinhubl SR, Berger PB, Mann JT 3rd et al.: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288(19), 2411-2420 (2002).
14. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al.: Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J. Am. Coll. Cardiol. 49(14), 1505-1516 (2007).
15. Ferreiro JL, Angiolillo DJ: Clopidogrel response variability: current status and future directions. Thromb. Haemost. 102(1), 7-14 (2009).
16. Angiolillo DJ, Ferreiro JL: Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions. Rev. Esp. Cardiol. 63(1), 60-76 (2010).
17. Jernberg T, Payne CD, Winters KJ et al.: Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur. Heart J. 27(15), 1166-1173 (2006).
18. Wiviott SD, Trenk D, Frelinger AL et al.: Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation - Thrombolysis in Myocardial Infarction 44 trial. Circulation 116(25), 2923-2932 (2007).
19. Capranzano P, Ferreiro JL, Angiolillo DJ: Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention. Expert Rev. Cardiovasc. Ther. 7(4), 361-369 (2009).
20. Wiviott SD, Braunwald E, McCabe CH et al.; for the TRITON-TIMI 38 Investigators: Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357(20), 2015-2021 (2007).
21. Kushner FG, Hand M, Smith SC et al.: Updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update). J. Am. Coll. Cardiol. 54(23), 2205-2241 (2009).
22. Capodanno D, Dharmashankar K, Angiolillo DJ: Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist. Expert Rev. Cardiovasc. Ther. 8(2), 151-158 (2010).
23. Wallentin L, Becker RC, Budaj A et al.: Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11), 1045-1057 (2009).
24. Ferreiro JL, Ueno M, Angiolillo DJ: Cangrelor: a review on its mechanism of action and clinical development. Expert Rev. Cardiovasc. Ther. 7(10), 1195-1201 (2009).
25. Harrington RA, Stone GW, McNulty S et al.: Platelet inhibition with cangrelor in patients undergoing PCI. N. Engl. J. Med. 361(24), 2318-2329 (2009).
26. Bhatt DL, Lincoff M, Gibson M et al.: Intravenous platelet blockade with cangrelor during PCI. N. Engl. J. Med. 361(24), 2330-2341 (2009).
27. Oestreich JH: Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events. Curr. Opin. Investig. Drugs 11(3), 340-348 (2010).
28. Steinhubl SR, Oh JJ, Oestreich JH, Ferraris S, Charnigo R, Akers WS: Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb. Res. 121(4), 527-534 (2008).
29. Dovlatova NL, Jakubowski JA, Sugidachi A Heptinstall S: The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J. Thromb. Haemost. 6(7), 1153-1159 (2008).
30. Stephens G, Gao D, Phillips DR, Andre P: Differential effects of anti-platelet drugs on thrombus formation and stability. J. Thromb. Haemost. 5(Suppl. 2), Abstract O-W-034 (2007).
31. Conley P, Jurek M, Stephens G et al.: A novel pharmacodynamic perfusion chamber assay reveals superior and unique antithrombotic activities of a direct-acting P2Y12 antagonist, PRT128, relative to clopidogrel. Blood 108(11), Abstract 900 (2006).
32. Angiolillo DJ, Shoemaker SB, Desai B et al.: Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 115(6), 708-716 (2007).
33. Haberstock-Debic H, Andre P, Delaney SM et al.: A functional pool of P2Y12 receptors exposed upon platelet activation persists in mice treated with high dose clopidogrel, and can be blocked by elinogrel, a direct acting, reversible P2Y12 inhibitor Thromb. Haemost. 7(Suppl. 2), Abstract PP-MO-045 (2009).
34. Haberstock-Debic H, Andre P, Delaney S et al.: The clopidogrel- insensitive pool of P2Y12 receptors exposed upon platelet activation contributes to thrombus formation and can be blocked by elinogrel, a direct acting, reversible P2Y12 inhibitor. Eur. Heart J. 30(Suppl.), Abstract 884 (2009).
35. Andre P, Conley PB, Deguzman F et al.: Combination of direct acting FXa inhibitor and P2Y12 antagonist at non-effective doses provides significant inhibition of arterial thrombosis. Circulation 118(Suppl.), Abstract 1718 (2008).
36. Andre P, DeGuzman F, Mills S et al.: Clopidogrel and prasugrel prolong primary hemostasis in the mouse beyond levels associated with P2Y12 inhibition. J. Thromb. Haemost. 7(Suppl. 2), Abstract AS-TH-022 (2009).
37. Desai M, Gretler D, Gu Z-M et al.: Metabolism and excretion of PRT060128, a new direct-acting, reversible P2Y12 inhibitor, in healthy human subjects. Ann. Meet. Exposition Am. Assoc. Pharm. Scientists Abstract T3312 (2008).
38. Lieu HD, Conley PB, Andre P et al.: Initial intravenous experience with PRT060128 (PRT128), an orally-available, direct-acting, and reversible P2Y12 inhibitor. J. Thromb. Haemost. 5(Suppl. 2), Abstract P-T-292 (2007).
39. Gretle DD, Conley PB, Andre P et al.: 'First in human' experience with PRT060128, a new direct-acting, reversible, P2Y12 inhibitor for IV and oral use. J. Am. Coll. Cardiol. 49(Suppl. 9), Abstract 1002-1128 (2007).
40. Gurbel PA, Bliden KP, Antonino MJ et al.: The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP 2C19*2 genotype: first experience in patients. J. Thromb. Haemost. 8(1), 43-53 (2009).
41. Conley PB, Andre P, Stephens G et al.: ADP-mediated aggregation as a pharmacodynamic assay underestimates the antithrombotic activity of elinogrel, a competitive, reversible P2Y12 inhibitor, relative to clopidogrel. J. Thromb. Haemost. 7, Suppl 2, Abstract PP-TH-027 (2009).
42. Folie BJ, McIntire LV: Mathematical analysis of mural thrombogenesis. Concentration profiles of platelet-activating agents and effects of viscous shear flow. Biophys. J. 56(6), 1121-1141 (1989).
43. Marín F, González-Conejero R, Capranzano P, Bass TA, Roldán V, Angiolillo DJ: Pharmacogenetics in cardiovascular antithrombotic therapy. J. Am. Coll. Cardiol. 54(12), 1041-1057 (2009).
44. Berger JS, Roe MT, Gibson CM et al.: Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid Reversal of Platelet Thrombosis with Intravenous Elinogrel Before PCI to Optimize Reperfusion in Acute Myocardial Infarction (ERASE MI) pilot trial. Am. Heart J. 158(6), 998.E1-1004.E1 (2009).